UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Lassen Therapeutics 1, Inc.

Petitioner

v.

Singapore Health Services PTE LTD., and
National University of Singapore
Patent Owner

CASE: Unassigned

Patent No. 10,106,603

PETITION FOR POST GRANT REVIEW



TABLE OF CONTENTS

Page

I.	INTR	TRODUCTION1				
II.	GROUNDS FOR STANDING PURSUANT TO 37 C.F.R. § 42.104(A)					
III.	MANDATORY NOTICES					
	A.	37 C.F.R. § 42.8(b)(1): REAL PARTY-IN-INTEREST	1			
	B.	37 C.F.R. § 42.8(b)(2): RELATED MATTERS	2			
	C.	37 C.F.R. §§ 42.8(b)(3) AND (4): LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION	2			
IV.	PAY	MENT OF FEES	3			
V.	TIME	TIME FOR FILING PETITION				
VI.		DENTIFICATION OF CHALLENGED CLAIMS AND RELIEF SOUGHT3				
VII.	'603	PATENT OVERVIEW	4			
VIII.	II. 37 C.F.R. § 42.104(b)(3): Claim Construction					
	A.	"method of treating fibrosis"	5			
	B.	"administering to the human subject in need of treatment a therapeutically effective amount of an Interleukin 11 receptor α (IL-11R α) antibody"	7			
	C.	"Interleukin 11 receptor α (IL-11Rα) antibody"	8			
	D.	"capable of inhibiting Interleukin 11 (IL-11) mediated signaling"				
	E.	"wherein the fibrosis is fibrosis of the heart, liver, kidney, or eye"	12			
IX.	Level of ordinary skill in the art					
X.	DETAILED GROUNDS FOR UNPATENTABILITY					
	A.	State of the Art	13			



TABLE OF CONTENTS

				Page
	B.	Lack	c of Written Description	22
	C.	Lack of Enablement		
		1.	The Nature of the Invention and Breadth of the Claims	28
		2.	State of the Art, Unpredictability of the Art, and the Level of Ordinary Skill	31
		3.	Lack of Direction or Guidance and the Absence of Working Examples	36
		4.	Quantity of Experimentation Required	36
	D.	Clai	ms 1-4, 6 and 8-10 are anticipated by Edwards	37
		1.	Claim 1	38
		2.	Claim 2	42
		3.	Claim 3	42
		4.	Claim 4	43
		5.	Claim 6	45
		6.	Claims 8-10	46
	E.	Clams 1-10 are obvious over Edwards with the knowledge of POSITA		
		1.	Claims 1-7	49
		2.	Claims 8-10	53
	F.		ns 1-10 are obvious over the combination of Edwards, nn, and Chegini	
		1.	Claims 1-7	54
		2.	Claims 8-10	61
XI.	CON	ICLUS	SION	62



PETITIONER'S EXHIBIT LIST

Exhibit No.	Description
1001	U.S. Patent No. 10,106,603 B2 (the '603 patent")
1002	Prosecution History of U.S. Patent No. 10,106,603 B2
1003	Declaration of Dr. Peter Bowers
1004	Declaration of Dr. Stephen Ledbetter
1005	U.S. Patent No. 8,182,814 B2 ("Baca")
1006	Victoria A. Barton et al., <i>Interleukin-11 Signals through the Formation of a Hexameric Receptor Complex</i> , 275 THE J. OF BIOLOGICAL CHEMISTRY 36197 (2000)
1007	Qingsheng Chen et al., <i>IL-11 Receptor</i> α in the Pathogenesis of <i>IL-13</i> Induced Inflammation and Remodeling, 174 J. IMMUNOL 2305 (2005)
1008	U.S. Patent Publication No. 2014/0219919 A1 ("Edwards")
1009	Weiliang Tang et al., Targeted Expression of IL-11 in the Murine Airway Causes Lymphocytic Inflammation, Bronchial Remodeling, and Airways Obstruction, 98 THE J. OF CLINICAL INVESTIGATION 2845 (1996)
1010	Thomas A. Wynn, Fibrotic Disease and the $T_H 1/T_H 2$ Paradigm, 4 NATURE REVIEWS IMMUNOLOGY 583 (2004)
1011	U.S. Patent Publication No. 2018/0186872 A1 ("Cook")
1012	Xiaoyu Yang et al., Developability studies before initiation of process development, 5 MABS 787 (2013)
1013	Łukasz Opaliński et al., High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1, 19 Int. J. Mol. Sci. 1435 (2018)





Exhibit No.	Description
1014	Ru Zhou & Rachel R. Caspi, <i>Ocular immune privilege</i> , F1000 BIOLOGY REPORTS (2010)
1015	Chrystel Blanc et al., Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Ra) and their use in studies of human mononuclear cells; 241 J. OF IMMUNOLOGICAL METHODS 43 (2000)
1016	Bryan Briney et al., Commonality despite exceptional diversity in the baseline human antibody repertoire, NATURE www.nature.com/nature (2019)
1017	David J. Curtis et al., Recombinant Soluble Interleukin-11 (IL-11) Receptor α-Chain Can Act as an IL-11 Antagonist, 90 BLOOD 4403 (1997)
1018	Martin Friedlander, <i>Fibrosis and diseases of the eye</i> , 117 THE J. OF CLINICAL INVESTIGATION 576 (2007)
1019	Christoph Garbers et al., <i>Plasticity and cross-talk of Interleukin 6-type cytokines</i> , 23 CYTOKINE & GROWTH FACTOR REVIEWS 85 (2012)
1020	Simon A. Jones & Brendan J. Jenkins, <i>Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer</i> , 18 NATURE REVIEWS IMMUNOLOGY 773 (2018)
1021	Sujin Kang et al., Therapeutic uses of anti-interleukin-6 receptor antibody, 27 INT'L IMMUNOLOGY 21 (2014)
1022	Rishi Matadeen et al., <i>The Dynamics of Signal Triggering in a gp130-Receptor Complex</i> ; 15 STRUCTURE 441 (2007)
1023	Norihiro Nishimoto et al., <i>Toxicity, Pharmacokinetics, and Dose-Finding Study of Repetitive Treatment with the Humanized Anti-Interleukin 6 Receptor Antibody MRA in Rheumatoid Arthritis. Phase I/II Clinical Study,</i> 30 J. Rheumatol 1426 (2003)



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

